For research use only. Not for therapeutic Use.
<p>
Fotemustine (S 10036) is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma.
</p>
<p>
Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. Fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively) [1].
</p>
| Catalog Number | I005484 |
| CAS Number | 92118-27-9 |
| Synonyms | S-10036 |
| Molecular Formula | C9H19ClN3O5P |
| Purity | ≥95% |
| Target | DNA alkylator/crosslinker |
| Solubility | DMSO：≥ 3 mg/mL |
| Storage | Store at -20°C |
| Reference | </br>1:Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib. Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, Giorello L, Merlo DF, Simeone E, Grimaldi AM, Curvietto M, Del Vecchio M, Bruzzi P, Ascierto PA.Oncotarget. 2016 Jul 13. doi: 10.18632/oncotarget.10589. [Epub ahead of print] PMID: 27418142 Free Article</br>2:Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. Lombardi G, Bellu L, Pambuku A, Della Puppa A, Fiduccia P, Farina M, D/’Avella D, Zagonel V.J Neurooncol. 2016 Jul;128(3):481-6. doi: 10.1007/s11060-016-2136-7. Epub 2016 May 11. PMID: 27165580 </br>3:Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. Maccalli C, Giannarelli D, Capocefalo F, Pilla L, Fonsatti E, Di Giacomo AM, Parmiani G, Maio M.Oncoimmunology. 2015 Aug 12;5(2):e1071007. eCollection 2016 Feb. PMID: 27057436 Free PMC Article</br>4:AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E.Neuro Oncol. 2016 Sep;18(9):1304-12. doi: 10.1093/neuonc/now035. Epub 2016 Mar 6. PMID: 26951379 </br>5:GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J.Clin Transl Oncol. 2016 Aug;18(8):805-12. doi: 10.1007/s12094-015-1444-2. Epub 2015 Nov 5. PMID: 26542177 </br>6:Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A.Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803. Epub 2015 Oct 12. PMID: 26458240 Free PMC Article</br>7:Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme. Liu Z, Zhang G, Zhu L, Wang J, Liu D, Lian L, Liu J, Lai T, Zhuang X.Biomed Res Int. 2015;2015:723612. doi: 10.1155/2015/723612. Epub 2015 Feb 18. PMID: 25789324 Free PMC Article</br>8:Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, Osti MF, Esposito V, Enrici RM.J Neurooncol. 2015 May;122(3):559-66. doi: 10.1007/s11060-015-1745-x. Epub 2015 Feb 22. PMID: 25702193 </br>9:B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. Roos WP, Quiros S, Krumm A, Merz S, Switzeny OJ, Christmann M, Loquai C, Kaina B.Oncotarget. 2014 Dec 30;5(24):12607-20. PMID: 25557167 Free PMC Article</br>10:Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M.Ann Oncol. 2015 Apr;26(4):798-803. doi: 10.1093/annonc/mdu577. Epub 2014 Dec 23. PMID: 25538176 |
